Mirati Therapeutics IncChange company Symbol lookupSelect an option...MRTX Mirati Therapeutics IncJKS JinkoSolar Holding Co LtdAGFY Agrify CorpYUM Yum! Brands IncMMND Mastermind IncGRTX Galera Therapeutics IncEVA Enviva IncSBLK Star Bulk Carriers CorpTSP TuSimple Holdings IncGLG TD Holdings IncGo
Change company Symbol lookup
Select an option...
MRTX Mirati Therapeutics Inc
JKS JinkoSolar Holding Co Ltd
AGFY Agrify Corp
YUM Yum! Brands Inc
MMND Mastermind Inc
GRTX Galera Therapeutics Inc
EVA Enviva Inc
SBLK Star Bulk Carriers Corp
TSP TuSimple Holdings Inc
GLG TD Holdings Inc
Health Care : Biotechnology | Small Cap Blend
Company profileMirati Therapeutics Inc is a United States-based clinical-stage biotechnology company that is focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. The Company is using its scientific expertise to develop novel solutions in two registration-enabling programs: adagrasib (MRTX849), an investigational small molecule, potent and selective KRASG12C inhibitor, as monotherapy and in combination with other agents, and sitravatinib, an investigational spectrum-selective inhibitor of receptor tyrosine kinases in combination with checkpoint inhibitor therapies. The Company is also advancing its differentiated preclinical portfolio, including MRTX1133, an investigational KRASG12D inhibitor, MRTX1719, an investigational PRMT5 inhibitor, and other oncology discovery programs.
|
|
|
|
| |
| Latest Earnings Beat Consensus (Q3 ending 09/2022) | Next Earnings Announcement | ||||||
|---|---|---|---|---|---|---|---|
| Q3 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced November 8, 2022 | -$3.09 | Q3 Consensus of 16 analysts | -$3.48 | Difference from consensus | 11.10% | Q4 Earnings will announce | (Unconfirmed) February 27, 2023 |
Quarterly Earnings History and Estimates
Show high-low estimates
Draw trendlines
Draw up to 3 lines inside the chart.
MRTX's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.